Gastric antisecretory treatment when PO is not possible eg, GERD in patients w/ esophagitis &/or severe symptoms of reflux. Healing of gastric ulcers associated w/ NSAID therapy. Prevention of gastric & duodenal ulcers associated w/ NSAID therapy in patients at risk. Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.
Gastric antisecretory treatment when PO is not possible 20-40 mg once daily. Reflux esophagitis 40 mg once daily. Symptomatic treatment of reflux disease, healing of gastric ulcers associated w/ NSAID therapy, prevention of gastric & duodenal ulcers associated w/ NSAID therapy 20 mg once daily. Prevention of gastric & duodenal ulcer rebleeding 80 mg bolus infusion over 30 min followed by 8 mg/hr continuous IV infusion over 3 days. Severe hepatic impairmentGERD Max: 20 mg daily. Bleeding ulcers Initially 80 mg IV infusion followed by 4 mg/hr continuous IV infusion over 71.5 hr.
Exclude gastric malignancy prior to treatment. Increased risk of GI infections eg, Salmonella & Campylobacter; subacute cutaneous lupus erythematosus; hip, wrist & spine fracture; Clostridium difficile-associated diarrhea. Severe hypomagnesaemia; vit B12 deficiency. Ensure adequate Ca & vit D intake in patients at risk of osteoporosis. Discontinue use for at least 5 days before CgA measurements. Long-term use. Not recommended in concomitant use w/ atazanavir. Concomitant use w/ digoxin, drugs causing hypomagnesaemia eg, diuretics. Severe renal insufficiency. Pregnancy. Not to be used during lactation.
A02BC05 - esomeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Sign Out
